Unfolding narratives, shaping futures

We're always working to initiate change for patients

This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.

UroGen® profile

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

See our pipeline

Our leadership

See full leadership team

News releases

Aug 21, 2025

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J. , Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in

Read story

Aug 7, 2025

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

ZUSDURI™   (mitomycin) for intravesical solution   now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) JELMYTO® achieved net product sales of $24 .2 million in Q2 2025, compared with $21.8

Read story

Aug 5, 2025

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J. , Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and

Read story

Events

Sep 8, 2025

H.C. Wainwright 27th Annual Global Healthcare Conference

Listen to webcast

Sep 4, 2025

Cantor Fitzgerald Global Healthcare Conference

Read more

about Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2025

Wells Fargo Healthcare Conference

Listen to webcast

Aug 7, 2025

UroGen Pharma Q2 2025 Earnings Call

Listen to webcast

Jun 13, 2025

UroGen Pharma ZUSDURI Approval Investor Call

Listen to webcast

May 28, 2025

TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Listen to webcast

May 12, 2025

UroGen Pharma Q1 2025 Earnings Call

Listen to webcast

Mar 10, 2025

UroGen Pharma Q4 2024 Earnings Call

Listen to webcast

Mar 3, 2025

TD Cowen 45th Annual Health Care Conference

Listen to webcast

Feb 20, 2025

Advancing Our Mission to Transform Cancer Care

Listen to webcast
Connect with us
For more information about our products